FDA Narrows Indication For Stryker’s Wingspan Intracranial Stent
This article was originally published in The Gray Sheet
Executive Summary
Agency restricts use of the device to a select patient population with severe intracranial stenosis and recurrent stroke after reviewing studies indicating the device could actually lead to increased rates of stroke and death.
You may also be interested in...
Off-Label Use Of Stryker Wingspan Stent Could Pose Serious Risks: US FDA
The agency issued a recent safety alert against off-label use of Stryker’s Wingspan Stent. Based on a postmarket study, regulators found higher rates of stroke and death in patients who were treated with the stent for other than its approved indication.
ISC 2018: WEAVE Post-Market Data Boost Stryker's Wingspan Brain Stent
Stryker's Wingspan intracranial stent, the subject of controversy several years ago when a post-market trial showed an unexpectedly high risk of adverse events with the device, can be deployed effectively with minimal risk in the specific patient population indicated on its label, results of the WEAVE study show.
Regulatory News In Brief
Intuitive Surgical responds to FDA investigation of increased adverse event reports. Groups call on FDA to change its Freedom of Information Act policy. More regulatory news.